New product Teglutik® obtained Drug Registration Certificate

Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) is pleased to announce that, on 31 May 2022, the Drug Registration Certificate for in-licensed product Teglutik® (Riluzole Oral Suspension) has been obtained from the China National Medical Products Administration (NMPA). Teglutik® has been approved to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (“ALS”).

The release as fetched from its publisher. leespharm.com ↗